Trust Investment Advisors Sells 700 Shares of Edwards Lifesciences Corp (NYSE:EW)

Trust Investment Advisors lessened its stake in shares of Edwards Lifesciences Corp (NYSE:EW) by 12.8% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 4,765 shares of the medical research company’s stock after selling 700 shares during the period. Trust Investment Advisors’ holdings in Edwards Lifesciences were worth $880,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. FTB Advisors Inc. bought a new stake in Edwards Lifesciences during the first quarter valued at about $25,000. Evolution Wealth Advisors LLC bought a new stake in Edwards Lifesciences during the second quarter valued at about $29,000. M&R Capital Management Inc. bought a new stake in Edwards Lifesciences during the second quarter valued at about $29,000. Field & Main Bank bought a new stake in Edwards Lifesciences during the first quarter valued at about $34,000. Finally, WP Advisors LLC bought a new stake in Edwards Lifesciences during the first quarter valued at about $35,000. 82.42% of the stock is owned by institutional investors and hedge funds.

In related news, VP Catherine M. Szyman sold 1,474 shares of the stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $177.92, for a total transaction of $262,254.08. Following the completion of the transaction, the vice president now directly owns 21,396 shares of the company’s stock, valued at $3,806,776.32. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Schack Wesley W. Von sold 3,000 shares of the stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $217.27, for a total value of $651,810.00. Following the transaction, the director now directly owns 1,737 shares of the company’s stock, valued at $377,397.99. The disclosure for this sale can be found here. Over the last three months, insiders have sold 144,422 shares of company stock valued at $28,198,586. 1.63% of the stock is owned by corporate insiders.

EW has been the subject of several recent research reports. BMO Capital Markets boosted their price target on Edwards Lifesciences from $204.00 to $224.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. BTIG Research reaffirmed a “hold” rating on shares of Edwards Lifesciences in a research note on Thursday, July 25th. Wells Fargo & Co upped their price objective on Edwards Lifesciences from $207.00 to $220.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Jefferies Financial Group upped their price objective on Edwards Lifesciences from $210.00 to $245.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Finally, Stifel Nicolaus upped their price objective on Edwards Lifesciences from $190.00 to $200.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and fourteen have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $204.74.

Shares of NYSE EW traded up $0.53 during mid-day trading on Friday, reaching $217.63. The company’s stock had a trading volume of 482,765 shares, compared to its average volume of 1,225,709. The company has a market cap of $45.15 billion, a price-to-earnings ratio of 46.30, a PEG ratio of 2.73 and a beta of 0.87. The company has a quick ratio of 2.48, a current ratio of 3.38 and a debt-to-equity ratio of 0.18. The firm’s fifty day simple moving average is $198.21. Edwards Lifesciences Corp has a 52 week low of $134.53 and a 52 week high of $219.71.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, July 23rd. The medical research company reported $1.38 earnings per share for the quarter, topping analysts’ consensus estimates of $1.33 by $0.05. Edwards Lifesciences had a return on equity of 31.25% and a net margin of 18.29%. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.04 billion. During the same quarter in the prior year, the company posted $1.24 earnings per share. The business’s quarterly revenue was up 15.2% compared to the same quarter last year. As a group, equities research analysts anticipate that Edwards Lifesciences Corp will post 5.34 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

See Also: How to Invest in Marijuana Stocks

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.